Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

Inclusion Criteria:

Metastatic adenocarcinoma of the breast (Stage IV)
Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy)
Minimum age 18 years
ECOG Performance status of 0, 1 or 2
Normal organ and marrow function as defined in the protocol

Exclusion Criteria:

Participants may not be receiving any other study agents
Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks
Any statin therapy within the last 3 weeks
Asian decent (including Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian origin)
Concomitant use of the following drugs: cyclosporine, fibrates, niacin, gemfibrozil, ketaconazole, spironolactone, cimetidine, warfarin, erythromycin, or protease inhibitors
Conditions predisposing to renal failure secondary to rhabdomyolysis
Recent history of heavy alcohol use as judged by the treating physician
Known to be pregnant (testing not required) or nursing
History of rhabdomyolysis on statin therapy
Known history of Hepatitis C or active hepatitis B infection (baseline testing not required)
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements